Great Lakes Advisors LLC Makes New $11.94 Million Investment in Boston Scientific Corporation $BSX

Great Lakes Advisors LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 279,760 shares of the medical equipment provider’s stock, valued at approximately $11,940,000.

Other large investors have also modified their holdings of the company. Kelleher Financial Advisors bought a new position in shares of Boston Scientific during the second quarter valued at approximately $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific during the 1st quarter valued at $28,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Canaccord Genuity Group lowered their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Citigroup decreased their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Truist Financial lowered their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Raymond James Financial restated an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of BSX opened at $50.51 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company’s fifty day moving average price is $46.15 and its 200-day moving average price is $58.50. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The firm has a market capitalization of $73.20 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.